R
Robert Gray
Researcher at Harvard University
Publications - 230
Citations - 40767
Robert Gray is an academic researcher from Harvard University. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 57, co-authored 208 publications receiving 35144 citations. Previous affiliations of Robert Gray include University of Pretoria & Mayo Clinic.
Papers
More filters
Journal ArticleDOI
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Jason P. Fine,Robert Gray +1 more
TL;DR: This article proposes methods for combining estimates of the cause-specific hazard functions under the proportional hazards formulation, but these methods do not allow the analyst to directly assess the effect of a covariate on the marginal probability function.
Journal ArticleDOI
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan B. Sandler,Robert Gray,Michael C. Perry,Julie R. Brahmer,Joan H. Schiller,Afshin Dowlati,Rogerio Lilenbaum,David H. Johnson +7 more
TL;DR: The addition of bevacizumab to paclitaxel plus carboplatin in the treatment of selected patients with non-small-cell lung cancer has a significant survival benefit with the risk of increased treatment-related deaths.
Journal ArticleDOI
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
TL;DR: In this paper, a class of tests developed for comparing the cumulative incidence of a particular type of failure among different groups is presented. The tests are based on comparing weighted averages of the hazards of the subdistribution for the failure type of interest.
Journal ArticleDOI
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
Joseph A. Sparano,Robert Gray,Della F. Makower,Kathleen I. Pritchard,Kathy S. Albain,Daniel F. Hayes,Daniel F. Hayes,Charles E. Geyer,Elizabeth Claire Dees,Matthew P. Goetz,John A. Olson,John A. Olson,Tracy Lively,Sunil Badve,Thomas J. Saphner,Lynne I. Wagner,Timothy J. Whelan,Matthew J. Ellis,Soonmyung Paik,William C. Wood,Peter M. Ravdin,Maccon M. Keane,Henry L. Gomez Moreno,Pavan S. Reddy,Timothy F. Goggins,Ingrid A. Mayer,Adam Brufsky,Deborah Toppmeyer,Virginia G. Kaklamani,Jeffery L. Berenberg,Jeffrey Abrams,George W. Sledge +31 more
TL;DR: In this paper, the authors performed a prospective trial involving 10,273 women with hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, axillary node-negative breast cancer.
Journal ArticleDOI
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
Joseph A. Sparano,Robert Gray,D. F. Makower,Kathleen I. Pritchard,Kathy S. Albain,Daniel F. Hayes,Charles E. Geyer,Elizabeth Claire Dees,E. A. Perez,John A. Olson,John A. Olson,J. A. Zujewski,J. A. Zujewski,Tracy Lively,Sunil Badve,Tom Saphner,Lynne I. Wagner,Timothy J. Whelan,Matthew J. Ellis,Matthew J. Ellis,Soonmyung Paik,Soonmyung Paik,William C. Wood,Peter M. Ravdin,M. Keane,H. L. Gomez Moreno,Pavan S. Reddy,Timothy F. Goggins,Ingrid A. Mayer,Adam Brufsky,Deborah Toppmeyer,Virginia G. Kaklamani,JN Atkins,Jeffrey L. Berenberg,George W. Sledge,George W. Sledge +35 more
TL;DR: In this article, a prospective trial involving women with hormone-receptor-positive, human epidermal growth factor receptor type 2 (HER2)-negative, axillary node-negative breast cancer with tumors of 1.1 to 5.0 cm in the greatest dimension (or 0.6 to 1.0cm in the intermediate or high tumor grade) who met established guidelines for the consideration of adjuvant chemotherapy on the basis of clinicopathologic features.